



**National Board of Directors**

**Chair**

Stephen R. O'Kane

**Chair Elect**

Cheryl A. Calhoun, CPA, MBA

**Secretary/Treasurer**

Michael V. Carstens

**Vice Chair, Mission Programs**

Sumita B. Khatri, MD, MS

**Past Chair**

Penny J. Schilz

**Directors**

Rabih I. Bechara, MD, FCCP

Larry Blumenthal, MBA

Anne E. Dixon, MD

David G. Hill, MD

Mark C. Johnson, MBA

Colleen M. McIntosh, JD, LL.M.

Sean R. Muldoon, MD

Joe Ochipinti

Jonathon K. Rosen

Kathleen M. Skambis, JD

Johnny A. Smith, Jr., MA

Victor Waters, MD, JD, FCLM

Sterling QL Yee, MBA

**National President and CEO**

Harold P. Wimmer

September 17, 2021

Dear Research Participant:

On behalf of the American Lung Association, we would like to personally thank you for participating in TRIM (Trial of Roflumilast in Asthma Management). Your contribution of time, energy and commitment is truly appreciated. Your personal involvement will help us get one step closer to our goal of finding improved treatments and an eventual cure for asthma.

If for some reason you haven't already stopped taking the study medication, you should stop taking it now. We will let you know the results of the study once they are published.

The American Lung Association understands how scientific discovery can impact the lives of many. As the nation's oldest voluntary organization, we are dedicated to funding research about lung diseases, including asthma. As part of this commitment to research, the American Lung Association and top medical centers around the country partnered to create the Airways Clinical Research Centers (ACRC) network. The ACRC is made up of several clinical research clinics nationwide, with populations diverse in age, race, ethnicity and asthma severity. Its mission is to develop practical, large clinical trials that will benefit patients directly. You can read more about the Lung Association's research program by clicking the following link: <https://www.lung.org/research>

We hope you benefited from your participation. We also hope you will consider joining another trial as we continue to search for improved asthma treatments.

Sincerely,

A handwritten signature in black ink that reads "Albert Rizzo".

Albert Rizzo, MD  
Chief Medical Officer

